| الوصف: |
Purpose:To determinerecurrence and retreatment patternsafter treatmentof severe retinopathy of Prematurity (ROP)with either 0.5 mg, 0.25 mg, or 0.125 mg ofintravitrealbevacizumab for retinopathy of prematurity. Methods: In this retrospective chart review,data wasexamined forbabies who hadsevereROP and were treated withintravitrealbevacizumab dosesofeither0.500mg, 0.250mg, or 0.125 mgat Riley Hospitalfor Childrenin Indianapolis from 2014 to 2021. Data collected included demographic information, past medical history, and characteristics of ROP. The data was statistically analyzed using SPSS software. Results: One eye was analyzed for each baby. Out of 85babies, 79babies were included in the study.26babies were treated with 0.125 mg bevacizumab,37with 0.25 mg, and16with 0.5 mg.Allbabiesshowed initial response to thebevacizumab,with61babies(77.2%)receiving retreatment with laser for either recurrence or persistent avascular retina. While thebabiestreated with lower doses had higher percentages of retreatment (23babies (88.5%) in the 0.125 mg, 29babies(78.4%) in the 0.25 mg, and 9babies (56.3%) in the 0.5 mg group), the difference was not statistically significant (p=0.069).Most of the retreatments were due to recurrence ofROP(0.125 mg: 20 (87.0%), 0.25 mg:19 (65.5%), 0.50 mg:8(88.9%))(p=0.339).On average, thebabies in the 0.125 mg group were retreatedwith laser at 3.4 weeks earlier gestational age and 4.7 weeks sooner after initial treatmentthan thehigher dosing groups,however, this difference was not statistically significant (p=0.181, p=0.287). Conclusion:Theoutcomes comparing three doses of intravitreal bevacizumab for severe ROP showed a slight variation in recurrence and retreatment patterns but no statistically significant difference in our study. |